Amicus Therapeutics (FOLD) Releases Earnings Results, Misses Expectations By $-0.04 EPS

Amicus Therapeutics (FOLD) reported quarterly earnings results on Tuesday, Aug-9-2016. The company reported $-0.40 earnings per share for the quarter, missing the analyst consensus estimate by $-0.04. Analysts had a consensus of $-0.36. Analysts expectations of $.17 million.

Many Wall Street Analysts have commented on Amicus Therapeutics. BofA/Merrill Initiated Amicus Therapeutics on May 18, 2016 to “Buy”, Price Target of the shares are set at $10.

Amicus Therapeutics closed down -0.06 points or -0.86% at $6.94 with 15,85,505 shares getting traded on Monday. Post opening the session at $7, the shares hit an intraday low of $6.835 and an intraday high of $7.1 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Aug 8, 2016, Hung Do (Chief Science Officer) sold 25,000 shares at $7.00 per share price. According to the SEC, on Aug 8, 2016, Jay Barth (Chief Medical Officer) sold 10,458 shares at $7.00 per share price. On Jun 6, 2016, Ellen Rosenberg (General Counsel & Corp. Secy) purchased 15,000 shares at $7.67 per share price, according to the Form-4 filing with the securities and exchange commission.

Amicus Therapeutics Inc. is a biopharmaceutical company. The Company focuses on the discovery development and commercialization of medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold) a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs including Fabry disease Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease SD-101 for Epidermolysis Bullosa (EB) as well as ERT products for Fabry disease Pompe disease and MPS I.

Amicus Therapeutics

Leave a Reply

Amicus Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amicus Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.